Cargando…

Aging: A cell source limiting factor in tissue engineering

Tissue engineering has yet to reach its ideal goal, i.e. creating profitable off-the-shelf tissues and organs, designing scaffolds and three-dimensional tissue architectures that can maintain the blood supply, proper biomaterial selection, and identifying the most efficient cell source for use in ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Khorraminejad-Shirazi, Mohammadhossein, Dorvash, Mohammadreza, Estedlal, Alireza, Hoveidaei, Amir Human, Mazloomrezaei, Mohsen, Mosaddeghi, Pouria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6828594/
https://www.ncbi.nlm.nih.gov/pubmed/31692986
http://dx.doi.org/10.4252/wjsc.v11.i10.787
_version_ 1783465381399101440
author Khorraminejad-Shirazi, Mohammadhossein
Dorvash, Mohammadreza
Estedlal, Alireza
Hoveidaei, Amir Human
Mazloomrezaei, Mohsen
Mosaddeghi, Pouria
author_facet Khorraminejad-Shirazi, Mohammadhossein
Dorvash, Mohammadreza
Estedlal, Alireza
Hoveidaei, Amir Human
Mazloomrezaei, Mohsen
Mosaddeghi, Pouria
author_sort Khorraminejad-Shirazi, Mohammadhossein
collection PubMed
description Tissue engineering has yet to reach its ideal goal, i.e. creating profitable off-the-shelf tissues and organs, designing scaffolds and three-dimensional tissue architectures that can maintain the blood supply, proper biomaterial selection, and identifying the most efficient cell source for use in cell therapy and tissue engineering. These are still the major challenges in this field. Regarding the identification of the most appropriate cell source, aging as a factor that affects both somatic and stem cells and limits their function and applications is a preventable and, at least to some extents, a reversible phenomenon. Here, we reviewed different stem cell types, namely embryonic stem cells, adult stem cells, induced pluripotent stem cells, and genetically modified stem cells, as well as their sources, i.e. autologous, allogeneic, and xenogeneic sources. Afterward, we approached aging by discussing the functional decline of aged stem cells and different intrinsic and extrinsic factors that are involved in stem cell aging including replicative senescence and Hayflick limit, autophagy, epigenetic changes, miRNAs, mTOR and AMPK pathways, and the role of mitochondria in stem cell senescence. Finally, various interventions for rejuvenation and geroprotection of stem cells are discussed. These interventions can be applied in cell therapy and tissue engineering methods to conquer aging as a limiting factor, both in original cell source and in the in vitro proliferated cells.
format Online
Article
Text
id pubmed-6828594
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-68285942019-11-05 Aging: A cell source limiting factor in tissue engineering Khorraminejad-Shirazi, Mohammadhossein Dorvash, Mohammadreza Estedlal, Alireza Hoveidaei, Amir Human Mazloomrezaei, Mohsen Mosaddeghi, Pouria World J Stem Cells Review Tissue engineering has yet to reach its ideal goal, i.e. creating profitable off-the-shelf tissues and organs, designing scaffolds and three-dimensional tissue architectures that can maintain the blood supply, proper biomaterial selection, and identifying the most efficient cell source for use in cell therapy and tissue engineering. These are still the major challenges in this field. Regarding the identification of the most appropriate cell source, aging as a factor that affects both somatic and stem cells and limits their function and applications is a preventable and, at least to some extents, a reversible phenomenon. Here, we reviewed different stem cell types, namely embryonic stem cells, adult stem cells, induced pluripotent stem cells, and genetically modified stem cells, as well as their sources, i.e. autologous, allogeneic, and xenogeneic sources. Afterward, we approached aging by discussing the functional decline of aged stem cells and different intrinsic and extrinsic factors that are involved in stem cell aging including replicative senescence and Hayflick limit, autophagy, epigenetic changes, miRNAs, mTOR and AMPK pathways, and the role of mitochondria in stem cell senescence. Finally, various interventions for rejuvenation and geroprotection of stem cells are discussed. These interventions can be applied in cell therapy and tissue engineering methods to conquer aging as a limiting factor, both in original cell source and in the in vitro proliferated cells. Baishideng Publishing Group Inc 2019-10-26 2019-10-26 /pmc/articles/PMC6828594/ /pubmed/31692986 http://dx.doi.org/10.4252/wjsc.v11.i10.787 Text en ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Review
Khorraminejad-Shirazi, Mohammadhossein
Dorvash, Mohammadreza
Estedlal, Alireza
Hoveidaei, Amir Human
Mazloomrezaei, Mohsen
Mosaddeghi, Pouria
Aging: A cell source limiting factor in tissue engineering
title Aging: A cell source limiting factor in tissue engineering
title_full Aging: A cell source limiting factor in tissue engineering
title_fullStr Aging: A cell source limiting factor in tissue engineering
title_full_unstemmed Aging: A cell source limiting factor in tissue engineering
title_short Aging: A cell source limiting factor in tissue engineering
title_sort aging: a cell source limiting factor in tissue engineering
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6828594/
https://www.ncbi.nlm.nih.gov/pubmed/31692986
http://dx.doi.org/10.4252/wjsc.v11.i10.787
work_keys_str_mv AT khorraminejadshirazimohammadhossein agingacellsourcelimitingfactorintissueengineering
AT dorvashmohammadreza agingacellsourcelimitingfactorintissueengineering
AT estedlalalireza agingacellsourcelimitingfactorintissueengineering
AT hoveidaeiamirhuman agingacellsourcelimitingfactorintissueengineering
AT mazloomrezaeimohsen agingacellsourcelimitingfactorintissueengineering
AT mosaddeghipouria agingacellsourcelimitingfactorintissueengineering